This study is intended to investigate the clinical efficacy of TTV vaccine combined with PD-1/PD-L1 inhibitor in the treatment of relapsed and refractory advanced solid tumours from a clinical perspective.
Male or female aged 18-75 years;
Subjects must have histologically- or cytologically-confirmed diagnosis of advanced solid tumor(s) and have progressed on or is not eligible for available standard therapy;
Subjects have at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (non-nodal lesions with longest diameter ≥ 10 mm, or nodal lesions with short diameter ≥ 15 mm);
ECOG score of 0-2, lifespan > 12 weeks;
The patient is diagnosed with central nervous system leukemia(symptoms, signs, imaging, cerebrospinal fluid);
White blood cell count ≥ 50×10^9/ L or patients with rapid disease progression can't be guaranteed to complete a full treatment cycle;
Patients with fungal, bacterial, viral or other uncontrollable infections or requiring four-level isolation treatment.
HIV, HBV and HCV positive;